{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:27:58Z","timestamp":1789140478013,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,9,3]],"date-time":"2014-09-03T00:00:00Z","timestamp":1409702400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s11095-014-1505-1","type":"journal-article","created":{"date-parts":[[2014,9,2]],"date-time":"2014-09-02T21:52:03Z","timestamp":1409694723000},"page":"898-909","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["In vivo and In vitro Evaluations of Intestinal Gabapentin Absorption: Effect of Dose and Inhibitors on Carrier-Mediated Transport"],"prefix":"10.1007","volume":"32","author":[{"given":"Malte Selch","family":"Larsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidsel","family":"Fr\u00f8lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha Kampp","family":"N\u00f8hr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten Uhd","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Garmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Kreilgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,3]]},"reference":[{"key":"1505_CR1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/(SICI)1098-1128(199903)19:2<149::AID-MED3>3.0.CO;2-B","volume":"19","author":"JS Bryans","year":"1999","unstructured":"Bryans JS, Wustrow DJ. 3-Substituted GABA analogs with central nervous system activity: a review. Med Res Rev. 1999;19:149\u201377.","journal-title":"Med Res Rev"},{"key":"1505_CR2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0920-1211(97)00084-3","volume":"29","author":"CP Taylor","year":"1998","unstructured":"Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. 1998;29:233\u201349.","journal-title":"Epilepsy Res"},{"key":"1505_CR3","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.janxdis.2012.07.009","volume":"26","author":"FJ Farach","year":"2012","unstructured":"Farach FJ, Pruitt LD, Jun JJ, Jerud AB, Zoellner LA, Roy-Byrne PP. Pharmacological treatment of anxiety disorders: current treatments and future directions. J Anxiety Disord. 2012;26:833\u201343.","journal-title":"J Anxiety Disord"},{"key":"1505_CR4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12272-013-0057-y","volume":"36","author":"A Kukkar","year":"2013","unstructured":"Kukkar A, Bali A, Singh N, Jaggi AS. Implications and mechanism of action of gabapentin in neuropathic pain. Arch Pharm Res. 2013;36:237\u201351.","journal-title":"Arch Pharm Res"},{"key":"1505_CR5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/9781444316667.ch41","volume-title":"The treatment of epilepsy","author":"ER Somerville","year":"2009","unstructured":"Somerville ER, Michell AW. Gabapentin. In: Shorvon S, Perucca E, Engel J, editors. The treatment of epilepsy. Oxford: Wiley-Blackwell; 2009. p. 519\u201326."},{"key":"1505_CR6","doi-asserted-by":"crossref","DOI":"10.1002\/047145026X","volume-title":"Absorption and drug development: solubility, permeability, and charge state","author":"A Avdeef","year":"2003","unstructured":"Avdeef A. Absorption and drug development: solubility, permeability, and charge state. Hoboken: Wiley; 2003."},{"key":"1505_CR7","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1023\/A:1018951214146","volume":"10","author":"BH Stewart","year":"1993","unstructured":"Stewart BH, Kugler AR, Thompson PR, Bockbrader HN. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res. 1993;10:276\u201381.","journal-title":"Pharm Res"},{"key":"1505_CR8","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1208\/aapsj070121","volume":"7","author":"J Madan","year":"2005","unstructured":"Madan J, Chawla G, Arora V, Malik R, Bansal AK. Unbiased membrane permeability parameters for gabapentin using boundary layer approach. AAPS J. 2005;7:224\u201330.","journal-title":"AAPS J"},{"key":"1505_CR9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0920-1211(98)00020-5","volume":"31","author":"BE Gidal","year":"1998","unstructured":"Gidal BE, DeCerce J, Bockbrader HN, Gonzalez J, Kruger S, Pitterle ME, et al. Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. Epilepsy Res. 1998;31:91\u20139.","journal-title":"Epilepsy Res"},{"key":"1505_CR10","doi-asserted-by":"crossref","unstructured":"Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2011:1\u201391.","DOI":"10.1002\/14651858.CD007938.pub2"},{"key":"1505_CR11","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1080\/01616412.1999.11740975","volume":"21","author":"MS Luer","year":"1999","unstructured":"Luer MS, Hamani C, Dujovny M, Gidal B, Cwik M, Deyo K, et al. Saturable transport of gabapentin at the blood\u2013brain barrier. Neurol Res. 1999;21:559\u201362.","journal-title":"Neurol Res"},{"key":"1505_CR12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0090-9556(25)06578-X","volume":"23","author":"LL Radulovic","year":"1995","unstructured":"Radulovic LL, T\u00fcrck D, von Hodenberg A, Vollmer KO, McNally WP, DeHart PD, et al. Disposition of gabapentin (neurontin) in mice, rats, dogs, and monkeys. Drug Metab Dispos. 1995;23:441\u20138.","journal-title":"Drug Metab Dispos"},{"key":"1505_CR13","first-page":"830","volume":"36","author":"KO Vollmer","year":"1986","unstructured":"Vollmer KO, von Hodenberg A, K\u00f6lle EU. Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Arzneimittelforschung. 1986;36:830\u20139.","journal-title":"Arzneimittelforschung"},{"key":"1505_CR14","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1124\/jpet.104.067959","volume":"311","author":"KC Cundy","year":"2004","unstructured":"Cundy KC, Annamalai T, Bu L, De Vera J, Estrela J, Luo W, et al. XP13512 [(\u00b1)-1-([(\u03b1-Isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther. 2004;311:324\u201333.","journal-title":"J Pharmacol Exp Ther"},{"key":"1505_CR15","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/sj.clpt.6100271","volume":"83","author":"TJ Urban","year":"2008","unstructured":"Urban TJ, Brown C, Castro RA, Shah N, Mercer R, Huang Y, et al. Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin Pharmacol Ther. 2008;83:416\u201321.","journal-title":"Clin Pharmacol Ther"},{"key":"1505_CR16","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1124\/jpet.104.082255","volume":"313","author":"TZ Su","year":"2005","unstructured":"Su TZ, Feng MR, Weber ML. Mediation of highly concentrative uptake of pregabalin by L-Type amino acid transport in chinese hamster ovary and Caco-2 cells. J Pharmacol Exp Ther. 2005;313:1406\u201315.","journal-title":"J Pharmacol Exp Ther"},{"key":"1505_CR17","first-page":"288","volume":"39","author":"S Naoki","year":"2007","unstructured":"Naoki S, Nakanishi K, Wada M, Fujita T. Uptake and transport characteristics of gabapentin in human intestinal cell line caco-2. Drug Metab Rev. 2007;39:288\u20139.","journal-title":"Drug Metab Rev"},{"key":"1505_CR18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s11095-006-9155-6","volume":"24","author":"TV Nguyen","year":"2007","unstructured":"Nguyen TV, Smith DE, Fleisher D. PEPT1 enhances the uptake of gabapentin via trans-stimulation of b0,+ exchange. Pharm Res. 2007;24:353\u201360.","journal-title":"Pharm Res"},{"key":"1505_CR19","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1023\/A:1010970809090","volume":"18","author":"N Piyapolrungroj","year":"2001","unstructured":"Piyapolrungroj N, Li C, Bockbrader H, Liu G, Fleisher D. Mucosal uptake of gabapentin (neurontin) vs. pregabalin in the small intestine. Pharm Res. 2001;18:1126\u201330.","journal-title":"Pharm Res"},{"key":"1505_CR20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.mam.2012.10.007","volume":"34","author":"D Fotiadis","year":"2013","unstructured":"Fotiadis D, Kanai Y, Palac\u00edn M. The SLC3 and SLC7 families of amino acid transporters. Mol Aspects Med. 2013;34:139\u201358.","journal-title":"Mol Aspects Med"},{"key":"1505_CR21","doi-asserted-by":"crossref","first-page":"34948","DOI":"10.1074\/jbc.274.49.34948","volume":"274","author":"G Rossier","year":"1999","unstructured":"Rossier G, Meier C, Bauch C, Summa V, Sordat B, Verrey F, et al. LAT2, a new basolateral 4F2hc\/CD98-associated amino acid transporter of kidney and intestine. J Biol Chem. 1999;274:34948\u201354.","journal-title":"J Biol Chem"},{"key":"1505_CR22","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1113\/jphysiol.2004.065037","volume":"558","author":"MH Dave","year":"2004","unstructured":"Dave MH, Schulz N, Zecevic M, Wagner CA, Verrey F. Expression of heteromeric amino acid transporters along the murine intestine. J Physiol. 2004;558:597\u2013610.","journal-title":"J Physiol"},{"key":"1505_CR23","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejps.2008.06.007","volume":"35","author":"M Larsen","year":"2008","unstructured":"Larsen M, Larsen BB, Fr\u00f8lund B, Nielsen CU. Transport of amino acids and GABA analogues via the human proton-coupled amino acid transporter, hPAT1: Characterization of conditions for affinity and transport experiments in Caco-2 cells. Eur J Pharm Sci. 2008;35:86\u201395.","journal-title":"Eur J Pharm Sci"},{"key":"1505_CR24","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1021\/mp300345e","volume":"9","author":"S Fr\u00f8lund","year":"2012","unstructured":"Fr\u00f8lund S, Langthaler L, Kall M, Holm R, Nielsen CU. Intestinal drug transport via the proton-coupled amino acid transporter, PAT1 (SLC36A1), is inhibited by Gly-Xaa dipeptides. Mol Pharm. 2012;9:2761\u20139.","journal-title":"Mol Pharm"},{"key":"1505_CR25","doi-asserted-by":"crossref","first-page":"G191","DOI":"10.1152\/ajpgi.2001.281.1.G191","volume":"281","author":"CU Nielsen","year":"2001","unstructured":"Nielsen CU, Amstrup J, Steffansen B, Frokjaer S, Brodin B. Epidermal growth factor inhibits glycylsarcosine transport and hPepT1 expression in a human intestinal cell line. Am J Physiol Gastrointest Liver Physiol. 2001;281:G191\u2013G9.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"1505_CR26","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1111\/j.1476-5381.2009.00620.x","volume":"159","author":"S Fr\u00f8lund","year":"2010","unstructured":"Fr\u00f8lund S, Marquez OC, Larsen M, Brodin B, Nielsen CU. delta-Aminolevulinic acid is a substrate for the amino acid transporter SLC36A1 (hPAT1). Br J Pharmacol. 2010;159:1339\u201353.","journal-title":"Br J Pharmacol"},{"key":"1505_CR27","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/BF02977671","volume":"28","author":"S Park","year":"2005","unstructured":"Park S, Kim JK, Kim IJ, Choi B, Jung KY, Lee S, et al. Reabsorption of neutral amino acids mediated by amino acid transporter LAT2 and TAT1 in the basolateral membrane of proximal tubule. Arch Pharm Res. 2005;28:421\u201332.","journal-title":"Arch Pharm Res"},{"key":"1505_CR28","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1074\/jbc.M210449200","volume":"278","author":"C Bauch","year":"2003","unstructured":"Bauch C, Forster N, Loffing-Cueni D, Summa V, Verrey F. Functional cooperation of epithelial heteromeric amino acid transporters expressed in Madin-Darby canine kidney cells. J Biol Chem. 2003;278:1316\u201322.","journal-title":"J Biol Chem"},{"key":"1505_CR29","first-page":"843","volume-title":"Antiepileptic drugs","author":"MJ Mclean","year":"1995","unstructured":"Mclean MJ. Gabapentin: chemistry, absorption, distribution, and elimination. In: Levy R, Mattson R, Meldrum B, editors. Antiepileptic drugs. New York: Raven; 1995. p. 843\u20139."},{"key":"1505_CR30","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1023\/A:1018866928335","volume":"16","author":"N Jezyk","year":"1999","unstructured":"Jezyk N, Li C, Stewart BH, Wu X, Bockbrader HN, Fleisher D. Transport of pregabalin in rat intestine and Caco-2 monolayers. Pharm Res. 1999;16:519\u201326.","journal-title":"Pharm Res"},{"key":"1505_CR31","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1124\/jpet.104.067934","volume":"311","author":"KC Cundy","year":"2004","unstructured":"Cundy KC, Branch R, Chernov-Rogan T, Dias T, Estrada T, Hold K, et al. XP13512 [(\u00b1)-1-([(\u03b1-Isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther. 2004;311:315\u201323.","journal-title":"J Pharmacol Exp Ther"},{"key":"1505_CR32","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/0016-5085(95)90466-2","volume":"108","author":"ME Mailliard","year":"1995","unstructured":"Mailliard ME, Stevens BR, Mann GE. Amino acid transport by small intestinal, hepatic, and pancreatic epithelia. Gastroenterology. 1995;108:888\u2013910.","journal-title":"Gastroenterology"},{"key":"1505_CR33","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1248\/bpb.31.1096","volume":"31","author":"CS Kim","year":"2008","unstructured":"Kim CS, Cho S-H, Chun HS, Lee S-Y, Endou H, Kanai Y, et al. BCH, an Inhibitor of system L amino acid transporters, induces apoptosis in cancer cells. Biol Pharm Bull. 2008;31:1096\u2013100.","journal-title":"Biol Pharm Bull"},{"key":"1505_CR34","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00726-005-0221-x","volume":"29","author":"S Fraga","year":"2005","unstructured":"Fraga S, Pinho MJ, Soares-da-Silva P. Expression of LAT1 and LAT2 amino acid transporters in human and rat intestinal epithelial cells. Amino Acids. 2005;29:229\u201333.","journal-title":"Amino Acids"},{"key":"1505_CR35","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/jn\/132.4.733","volume":"132","author":"S Fraga","year":"2002","unstructured":"Fraga S, Serr\u00e3o MP, Soares-da-Silva P. l-Type amino acid transporters in two intestinal epithelial cell lines function as exchangers with neutral amino acids. J Nutr. 2002;132:733\u20138.","journal-title":"J Nutr"},{"key":"1505_CR36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-1211(00)00117-0","volume":"40","author":"BE Gidal","year":"2000","unstructured":"Gidal BE, Radulovic LL, Kruger S, Rutecki P, Pitterle M, Bockbrader HN. Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res. 2000;40:123\u20137.","journal-title":"Epilepsy Res"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-014-1505-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-014-1505-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-014-1505-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T12:47:41Z","timestamp":1746362861000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-014-1505-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,3]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["1505"],"URL":"https:\/\/doi.org\/10.1007\/s11095-014-1505-1","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,3]]}}}